###begin article-title 0
###xml 34 39 <span type="species:ncbi:9606">Human</span>
Molecular Basis of Recognition of Human Osteopontin by 23C3, a Potential Therapeutic Antibody for Treatment of Rheumatoid Arthritis
###end article-title 0
###begin p 1
J.D., S.H. and C.Z. contributed equally to this work.
###end p 1
###begin p 2
This document may be redistributed and reused, subject to .
###end p 2
###begin title 3
Abstract
###end title 3
###begin p 4
###xml 338 344 <span type="species:ncbi:10090">murine</span>
Osteopontin plays an important role in the development and perpetuation of rheumatoid arthritis (RA). Antibodies targeting osteopontin have shown promising therapeutic benefits against this disease. We have previously reported a novel anti-RA monoclonal antibody, namely, 23C3, and shown it capable of alleviating the symptoms of RA in a murine collagen-induced arthritis model, restoring the cytokine production profile in joint tissues, and reducing T-cell recall responses to collagen type II. We describe here the crystal structure of 23C3 in complex with its epitope peptide. Analyses of the complex structure reveal the molecular mechanism of osteopontin recognition by 23C3. The peptide folds into two tandem beta-turns, and two key residues of the peptide are identified to be critical for the recognition by 23C3: TrpP43 is deeply embedded into a hydrophobic pocket formed by AlaL34, TyrL36, LeuL46, TyrL49, PheL91, and MetH102 and therefore has extensive hydrophobic interactions with 23C3, while AspP47 has a network of hydrophilic interactions with residues ArgH50, ArgH52, SerH53, and AsnH56 of the antibody. Besides the complementarity-determining region loops, the framework region L2 of 23C3 is also shown to interact with the epitope peptide, which is not common in the antibody-antigen interactions and thus could be exploited in the engineering of 23C3. These results not only provide valuable information for further improvement of 23C3 such as chimerization or humanization for its therapeutic application, but also reveal the features of this specific epitope of osteopontin that may be useful for the development of new antibody drugs against RA.
###end p 4
###begin title 5
Abbreviations
###end title 5
###begin title 6
Keywords
###end title 6
###begin p 7
###xml 182 185 182 185 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1&#8211;3</sup>
###xml 182 185 182 185 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="bib1 bib2 bib3" ref-type="bibr"><sup>1&#8211;3</sup></xref>
###xml 653 656 649 652 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">4&#8211;6</sup>
###xml 653 656 649 652 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="bib4 bib5 bib6" ref-type="bibr"><sup>4&#8211;6</sup></xref>
###xml 409 417 <span type="species:ncbi:9606">patients</span>
The pathogenesis of rheumatoid arthritis (RA), a chronic autoimmune disease, involves accumulation of T lymphocytes in the synovial compartment and destruction of cartilage and bone.1-3 Several antirheumatic drugs are available in the market including two monoclonal antibody (mAb) drugs against tumor necrosis factor-alpha, namely, Infliximab (Centocor) and Adalimumab (Abbott). However, about 20-30% of the patients treated do not respond to the antibodies and some drugs lose efficacy or accumulate toxicity over time, demanding development of new strategies for the treatment of RA, probably against other factors involved in the pathogenesis of RA.4-6
###end p 7
###begin p 8
###xml 283 284 283 284 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">7</sup>
###xml 283 284 283 284 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="bib7" ref-type="bibr"><sup>7</sup></xref>
###xml 354 361 354 361 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
###xml 480 481 476 477 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">v</sub>
###xml 485 486 478 479 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</sub>
###xml 493 494 482 483 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">v</sub>
###xml 498 499 484 485 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1</sub>
###xml 506 507 488 489 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">v</sub>
###xml 511 512 490 491 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">5</sub>
###xml 523 524 498 499 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">8</sub>
###xml 528 529 500 501 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1</sub>
###xml 548 552 520 524 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">8&#8211;10</sup>
###xml 548 552 520 524 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="bib8 bib9 bib10" ref-type="bibr"><sup>8&#8211;10</sup></xref>
###xml 562 563 530 531 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">9</sub>
###xml 573 574 537 538 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">4</sub>
###xml 641 646 605 610 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">11&#8211;13</sup>
###xml 641 646 605 610 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="bib11 bib12 bib13" ref-type="bibr"><sup>11&#8211;13</sup></xref>
###xml 745 746 706 707 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1</sub>
###xml 791 793 752 754 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">14</sup>
###xml 791 793 752 754 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="bib14" ref-type="bibr"><sup>14</sup></xref>
###xml 1019 1021 980 982 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">15</sup>
###xml 1019 1021 980 982 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="bib15" ref-type="bibr"><sup>15</sup></xref>
###xml 1177 1179 1138 1140 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">16</sup>
###xml 1177 1179 1138 1140 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="bib16" ref-type="bibr"><sup>16</sup></xref>
###xml 1221 1222 1182 1183 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">H</sub>
###xml 1242 1244 1203 1205 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">17</sup>
###xml 1242 1244 1203 1205 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="bib17" ref-type="bibr"><sup>17</sup></xref>
###xml 1291 1293 1252 1254 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">18</sup>
###xml 1291 1293 1252 1254 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="bib18" ref-type="bibr"><sup>18</sup></xref>
###xml 1343 1345 1304 1306 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">19</sup>
###xml 1343 1345 1304 1306 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="bib19" ref-type="bibr"><sup>19</sup></xref>
###xml 1451 1453 1412 1414 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">20</sup>
###xml 1451 1453 1412 1414 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="bib20" ref-type="bibr"><sup>20</sup></xref>
###xml 622 627 <span type="species:ncbi:9606">human</span>
One such target is osteopontin, also known as early T-cell activation gene-1. It is one of the major noncollagenous bone matrix proteins and is expressed at elevated level at the inflammation site in various cell types including epithelial cells, mesenchymal cells, and immune cells.7 The protein is usually phosphorylated and can be cleaved by thrombin in vivo. When cleaved, the N-terminal fragment is capable of binding to various cell surface receptors such as integrins alphavbeta3, alphavbeta1, alphavbeta5, and alpha8beta1 via its RGD motif,8-10 and alpha9 and alpha4 integrins via a crypt region (162SVVYGLR168 of human osteopontin);11-13 both the N-terminal and C-terminal fragments can bind to CD44 variants with the assistance of beta1 integrins independently of the RGD sequence.14 Considering the various interactions between osteopontin and multiple cell receptors, it is not surprising that osteopontin exerts diverse functions in immunity, infection, and cancer (reviewed in the work of Denhardt and Guo15). Specifically, the multifaceted protein is involved in various aspects of immunity: osteopontin is considered an early component of cell-mediated immunity16 and seems to play a complicated role in TH2 effector responses17 and to mediate natural killer T-cell function.18 Moreover, osteopontin prevents monocyte apoptosis19 and seems to regulate the expression of cell-surface CD44 on macrophages and to modulate CD44 activities.20
###end p 8
###begin p 9
###xml 185 190 185 190 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">21,22</sup>
###xml 185 190 185 190 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="bib21 bib22" ref-type="bibr"><sup>21,22</sup></xref>
###xml 244 245 240 241 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">v</sub>
###xml 251 252 244 245 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1</sub>
###xml 280 282 273 275 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">21</sup>
###xml 280 282 273 275 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="bib21" ref-type="bibr"><sup>21</sup></xref>
###xml 504 506 497 499 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">21</sup>
###xml 504 506 497 499 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="bib21" ref-type="bibr"><sup>21</sup></xref>
###xml 695 697 688 690 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">21</sup>
###xml 695 697 688 690 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="bib21" ref-type="bibr"><sup>21</sup></xref>
An important role of osteopontin in amplification and perpetuation of RA is suggested by the confined expression of osteopontin in synovial fluid (SF) and synovial tissue of RA patients21,22 and the co-expression of osteopontin receptors (alphav, beta1 and CD44) in T cells in SF.21 In addition, when T cells are treated with RA-SF, osteopontin expression is elevated; on the other hand, overexpression of osteopontin induces proinflammatory chemokines and cytokines and activates nuclear factor-kappa B.21 Osteopontin deficiency is consistently shown to prevent the destruction of joint cartilage and joint swelling through suppression of chondrocyte apoptosis and angiogenesis in the RA model.21
###end p 9
###begin p 10
###xml 182 187 182 187 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">23&#8211;25</sup>
###xml 182 187 182 187 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="bib23 bib24 bib25" ref-type="bibr"><sup>23&#8211;25</sup></xref>
###xml 362 363 358 359 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">9</sub>
###xml 373 374 365 366 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">4</sub>
###xml 435 437 427 429 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">18</sup>
###xml 435 437 427 429 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="bib18" ref-type="bibr"><sup>18</sup></xref>
###xml 624 626 616 618 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">24</sup>
###xml 624 626 616 618 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="bib24" ref-type="bibr"><sup>24</sup></xref>
###xml 830 832 822 824 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">23</sup>
###xml 830 832 822 824 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="bib23" ref-type="bibr"><sup>23</sup></xref>
###xml 266 271 <span type="species:ncbi:10090">mouse</span>
###xml 573 579 <span type="species:ncbi:10090">murine</span>
###xml 715 720 <span type="species:ncbi:9606">human</span>
###xml 812 829 <span type="species:ncbi:9541">cynomolgus monkey</span>
Due to the association between osteopontin and RA, several anti-osteopontin antibodies have been developed and studies of these antibodies in animal RA models show promising results.23-25 The antibody M5 recognizes and binds to a cryptic epitope of thrombin-cleaved mouse osteopontin (147SLAYGLR153) and thereby blocks the binding of cleaved osteopontin to alpha9 and alpha4 integrins, which result in abrogation of monocyte migration.18 Treatment with M5 leads to inhibition of synovial proliferation, bone resorption, and inflammatory reaction in arthritic joints in the murine RA model induced by mAb/lipopolysaccharides.24 Another mAb, 2K1 or its chimeric form C2K1, recognizes the equivalent epitope region of human osteopontin (162SVVYGLR168) and is shown to ameliorate collagen-induced arthritis (CIA) in cynomolgus monkey.23
###end p 10
###begin p 11
###xml 126 128 126 128 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">25</sup>
###xml 126 128 126 128 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="bib25" ref-type="bibr"><sup>25</sup></xref>
###xml 648 650 648 650 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">25</sup>
###xml 648 650 648 650 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="bib25" ref-type="bibr"><sup>25</sup></xref>
###xml 935 937 935 937 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">25</sup>
###xml 935 937 935 937 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="bib25" ref-type="bibr"><sup>25</sup></xref>
###xml 1177 1179 1177 1179 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">25</sup>
###xml 1177 1179 1177 1179 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="bib25" ref-type="bibr"><sup>25</sup></xref>
###xml 36 42 <span type="species:ncbi:10090">murine</span>
###xml 155 159 <span type="species:ncbi:10090">mice</span>
###xml 280 284 <span type="species:ncbi:10090">Mice</span>
###xml 390 394 <span type="species:ncbi:10090">mice</span>
###xml 482 488 <span type="species:ncbi:10090">murine</span>
###xml 635 641 <span type="species:ncbi:10090">murine</span>
Recently, we have developed a novel murine anti-osteopontin mAb, namely, 23C3, which is of great potential in treatment of RA.25 Administration of 23C3 to mice with CIA not only strongly suppresses the development of CIA but also decreases the severity of the existing arthritis. Mice treated with 23C3 showed a cytokine production profile in joint tissues similar to that of the wild-type mice and reduced T-cell recall responses to collagen type II. We have also produced another murine mAb, F8E11, which is also included for the same assay, however, it shows much weaker efficacy for the treatment of the established disease in the murine model.25 As both F8E11 and 23C3 are capable of inhibiting monocyte migration, the robust therapeutic effect of 23C3 may be attributed to its ability to promote the apoptosis of activated T cells by inhibition of nuclear factor-kappa B and alteration of the expression of preapoptotic proteins,25 which may be unique, as neither M5 nor 2K1 is reported to be capable of induction of cell apoptosis. Intriguingly, 23C3 recognizes a distinct epitope motif (43WLNPDP48) of the full-length osteopontin, which may account for the differences.25 In this study, we report the crystal structure of the Fab fragment of 23C3 in complex with its epitope peptide of osteopontin. Our results reveal the structural basis for the 23C3 recognition of osteopontin and provide hints for further development of mAb drugs for the treatment of RA.
###end p 11
###begin title 12
The structure of the 23C3 Fab
###end title 12
###begin p 13
###xml 196 198 196 198 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">25</sup>
###xml 196 198 196 198 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="bib25" ref-type="bibr"><sup>25</sup></xref>
###xml 304 305 304 305 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">R</italic>
###xml 333 334 333 334 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">R</italic>
###xml 352 359 352 359 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="tbl1" ref-type="table">Table 1</xref>
###xml 361 367 361 367 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="fig1" ref-type="fig">Fig. 1</xref>
The Fab fragment of the anti-osteopontin mAb 23C3 was co-crystallized with a 12-mer peptide (40VATWLNPDPSQK51) that contains the previously mapped epitope region of osteopontin recognized by 23C3.25 The structure of 23C3 Fab in complex with the epitope peptide was determined to 2.8 A resolution with an R-factor of 24.8% and a free R-factor of 29.2% (Table 1, Fig. 1). There is one Fab-peptide complex in an asymmetric unit. Overall, the complex exhibits good geometry and has well-defined electron density even at the conserved loop region between GlyH131 and SerH137, which is disordered in many other Fab structures.
###end p 13
###begin p 14
###xml 89 90 89 90 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">L</sub>
###xml 93 94 93 94 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">L</sub>
###xml 97 98 97 98 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">H</sub>
###xml 105 107 105 107 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">H1</sub>
###xml 109 115 109 115 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="fig1" ref-type="fig">Fig. 1</xref>
###xml 164 165 164 165 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">H</sub>
###xml 170 171 170 171 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">L</sub>
###xml 177 179 177 179 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">H1</sub>
###xml 184 185 184 185 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">L</sub>
###xml 266 268 256 258 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">26</sup>
###xml 266 268 256 258 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="bib26" ref-type="bibr"><sup>26</sup></xref>
###xml 411 413 401 403 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">27</sup>
###xml 411 413 401 403 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="bib27" ref-type="bibr"><sup>27</sup></xref>
###xml 554 556 544 546 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">28</sup>
###xml 554 556 544 546 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="bib28" ref-type="bibr"><sup>28</sup></xref>
###xml 617 623 607 613 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="fig1" ref-type="fig">Fig. 1</xref>
###xml 813 815 790 792 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">29</sup>
###xml 813 815 790 792 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="bib29" ref-type="bibr"><sup>29</sup></xref>
###xml 829 834 806 811 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">30,31</sup>
###xml 829 834 806 811 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="bib30 bib31" ref-type="bibr"><sup>30,31</sup></xref>
###xml 943 945 920 922 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">31</sup>
###xml 943 945 920 922 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="bib31" ref-type="bibr"><sup>31</sup></xref>
###xml 542 548 <span type="species:ncbi:10090">murine</span>
The Fab fragment displays a canonical Fab structure with four immunoglobulin domains of VL, CL, VH, and CH1 (Fig. 1a). The elbow angle relating the disposition of VH to VL and CH1 to CL is about 150degrees, consistent with the fact that 23C3 has a kappa light chain.26 The complementarity-determining region (CDR) loops L1, L2, L3, H1, and H2 belong to Chothia canonical classes 2, 1, 1, 1, and 4, respectively.27 The CDR loop H3 of 23C3 contains only five residues, which is significantly shorter than the average length of 8.7 residues for murine mAbs.28 Interestingly, the Fab is glycosylated at AsnH57 of CDR H2 (Fig. 1a). An N-linked core tetrasaccharide (MANalpha-1,3MANbeta-1,4GlcNAcbeta-1,4GlcNAcbeta-1-AsnH57) was modeled without ambiguity. N-linked glycosylation of mAbs in both framework regions (FWRs)29 and CDR loops30,31 has been reported, and sugar chains on the CDR loops may also participate in the interactions with antigens.31 In our structure, there is no interaction between the sugar chain and the bound peptide. Due to the lack of a structure of the full-length osteopontin, the possibility that the sugar chain might be involved in the recognition of the full-length antigen cannot be excluded.
###end p 14
###begin title 15
The structure of the bound peptide
###end title 15
###begin p 16
###xml 114 120 114 120 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="fig1" ref-type="fig">Fig. 1</xref>
###xml 136 142 136 142 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="fig1" ref-type="fig">Fig. 1</xref>
###xml 326 328 320 322 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">32</sup>
###xml 326 328 320 322 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="bib32" ref-type="bibr"><sup>32</sup></xref>
The bound peptide has well-defined electron density (from ThrP42 to GlnP50) except for several terminal residues (Fig. 1b). As shown in Fig. 1, the peptide displays a twisted structure and is composed of the N-terminal two tandem beta-turns (beta-turn is the most common structural element of antigens in mAb-peptide complexes32) and the two C-terminal extended residues (SerP49 and GlnP50). The first beta-turn (ThrP42 to AsnP45) is of type I and the second (AsnP45 to ProP48) is of type VIII. The conformation of the peptide is mainly stabilized by the interactions between the peptide and the Fab (see the discussion later), while a hydrogen bond between the main-chain amide of AspP47 and the side-chain carbonyl of AsnP45 (2.88 A) also contributes to the stability.
###end p 16
###begin title 17
The interactions between the Fab and peptide
###end title 17
###begin p 18
###xml 347 353 347 353 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="fig2" ref-type="fig">Fig. 2</xref>
###xml 356 358 356 358 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">33</sup>
###xml 356 358 356 358 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="bib33" ref-type="bibr"><sup>33</sup></xref>
###xml 668 669 668 669 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
###xml 707 708 707 708 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
###xml 735 737 735 737 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">34</sup>
###xml 735 737 735 737 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="bib34" ref-type="bibr"><sup>34</sup></xref>
###xml 929 931 929 931 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">35</sup>
###xml 929 931 929 931 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="bib35" ref-type="bibr"><sup>35</sup></xref>
###xml 1046 1054 1046 1054 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="tbl2" ref-type="table">Tables 2</xref>
###xml 1059 1061 1059 1061 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="app1" ref-type="sec">S1</xref>
###xml 1066 1072 1066 1072 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="fig2" ref-type="fig">Fig. 2</xref>
###xml 1136 1137 1136 1137 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
###xml 1152 1153 1152 1153 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
###xml 1169 1170 1169 1170 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
###xml 1186 1187 1186 1187 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
###xml 1208 1209 1208 1209 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
###xml 1280 1281 1280 1281 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
###xml 1471 1473 1471 1473 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">32</sup>
###xml 1471 1473 1471 1473 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="bib32" ref-type="bibr"><sup>32</sup></xref>
In the complex structure, the peptide is bound in a pocket formed by the CDR loops and the tip of the FWR L2 (defined by Kabat definition). CDR loops L1, L3, H1, H2, and H3 participate in the interactions with the peptide, while loop L2 makes no direct contact with the peptide, as frequently observed in antipeptide or antihapten Fab structures (Fig. 2a).33 Uncommonly, some residues of the FWR L2 (including TyrL36, LeuL46, and TyrL49) have van der Waals contacts with the peptide, probably due to the deep embedment of the side chain of TrpP43 into the Fab (see detailed discussion later). The buried surface area (BSA) of the interaction interface is about 591.3 A2 within the average range of 400-700 A2 for mAb-peptide complexes,34 accounting for 47.4% of the total peptide surface area. The shape complementarity value of this complex is 0.80, much higher than the average value (0.64-0.68) for antibody-antigen complexes.35 Between the Fab and the peptide, nine hydrogen bonds, one salt bridge, and 126 van der Waals contacts are formed (Tables 2 and S1 and Fig. 2b and c). The CDR loops L1, L3, H1, H2, and H3 contribute 23.0 A2 (5.0%), 74.2 A2 (15.5%), 76.1 A2 (15.9%), 98.6 A2 (20.6%), and 132.9 A2 (27.7%) of the BSA, respectively. Additionally, FWR L2 also has 74.4 A2 (15.5%) of the BSA. These results are consistent with the notion that the H chain makes more interactions than the L chain when a mAb binds to a small-molecule antigen or a peptide antigen.32
###end p 18
###begin p 19
###xml 448 449 448 449 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
###xml 451 457 451 457 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="fig2" ref-type="fig">Fig. 2</xref>
###xml 857 863 857 863 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="fig2" ref-type="fig">Fig. 2</xref>
Analysis of the complex structure shows that all of the detected nine residues of the peptide interact with the 23C3 Fab and, particularly TrpP43 and AspP47, are the key residues recognized by 23C3. Specifically, the aromatic residue TrpP43 has a large hydrophobic indole group buried in a deep hydrophobic cage formed by AlaL34, TyrL36, LeuL46, TyrL49, PheL91, and MetH102, forming 46 van der Waals contacts and contributing a large BSA of 233.0 A2 (Fig. 2d). This residue alone contributes 36.5% of all the van der Waals contacts between the Fab and the peptide and 33.1% of all the BSA of the peptide. Additionally, the main-chain carbonyl of TrpP43 forms a hydrogen bond with the side-chain amide of GlnH101 of CDR loop H3. The acidic residue AspP47 is embedded into a positively charged cleft to form electrostatic interactions with ArgH50 and ArgH52 (Fig. 2e). The side chain of AspP47 has three hydrogen-bonding interactions with SerH53 and AsnH56, and its main-chain carbonyl forms a hydrogen bond with the side chain of ArgH52 as well. These interactions make AspP47 the most important contributor for the hydrophilic interactions between the peptide and the Fab.
###end p 19
###begin p 20
###xml 365 366 365 366 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">R</italic>
###xml 394 395 394 395 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">R</italic>
###xml 413 420 413 420 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="tbl1" ref-type="table">Table 1</xref>
###xml 508 515 508 515 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="app1" ref-type="sec">Fig. S1</xref>
###xml 594 599 594 595 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#945;</sup>
To further validate the critical roles of TrpP43 and AspP47 in the binding of 23C3, we carried out structural studies of the 23C3 Fab in complexes with the mutant peptides containing single mutation W43A or D47A, or double mutations W43A/D47A. The crystal structure of the 23C3 Fab in complex with the W43A mutant peptide was determined at 2.8 A resolution with an R-factor of 24.1% and a free R-factor of 29.7% (Table 1). The structure of the mutant complex resembles that of the wild-type peptide complex (Fig. S1). Superposition of the two complexes yields an RMSD of 0.4 A for 436 aligned Calpha atoms. In this mutant peptide complex, only seven (LeuP44 to GlnP50) of the nine peptide residues (ThrP42 to GlnP50) observed in the wild-type peptide complex could be defined with clear electron density and the two N-terminal residues ThrP42 and AlaP43 are disordered, indicating that the binding of this region with the Fab is substantially impaired due to the loss of the hydrophobic interactions caused by the W43A mutation. Moreover, crystallization of the 23C3 Fab in complex with the D47A or W43A/D47A mutant peptide was unsuccessful so far. It is most likely that the D47A mutation of the peptide would disrupt the extensive hydrophilic interactions of the peptide with the Fab and lead to the loss of the peptide's ability to bind the Fab. These results support our notion that TrpP43 and AspP47 are essential for the binding of 23C3.
###end p 20
###begin p 21
###xml 80 82 80 82 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">25</sup>
###xml 80 82 80 82 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="bib25" ref-type="bibr"><sup>25</sup></xref>
###xml 128 134 128 134 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="fig2" ref-type="fig">Fig. 2</xref>
###xml 137 145 137 145 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="tbl2" ref-type="table">Tables 2</xref>
###xml 150 152 150 152 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="app1" ref-type="sec">S1</xref>
Although less important, the other residues within the mapped epitope 43WLNPDP4825 are also involved in the binding of the Fab (Fig. 2b, Tables 2 and S1). The side chains of residues LeuP44 and AsnP45 stretch out against the Fab-peptide interaction interface and each forms 3 van der Waals contacts. The main-chain carbonyl of ProP46 forms a hydrogen bond with the main-chain amide of AlaH33. The side chain of ProP46 is surrounded by a hydrophobic concave formed by residues LeuH31 and TyrH32 and forms 14 van der Waals contacts. The side chain of ProP48 is covered by AsnP45 and points to the interface forming 7 van der Waals contacts. Besides the 43WLNPDP48 motif, the other three residues (ThrP42, SerP49, and GlnP50) also contribute some van der Waals contacts with the Fab. The side chains of SerP49 and GlnP50 each form a hydrogen bond with the side chain of ArgH52 and the main-chain carbonyl of PheL91, respectively.
###end p 21
###begin p 22
###xml 248 249 244 245 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">L</sub>
###xml 255 256 251 252 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">H</sub>
It is worth noting that besides CDRs, three conserved kappa chain residues of FWR L2 (TyrL36, LeuL46, and TyrL49) are also involved in the interactions between the peptide and the Fab in addition to their typical roles in the interactions between VL and VH domains. In our structure, they all make van der Waals contacts with the peptide due to the deep embedment of TrpP43, which is rare, as residues TyrL36 and LeuL46 generally do not participate in the Fab-antigen interactions and TyrL49 is only occasionally found in interactions between the Fab and nuclear acids or hapten antigens.
###end p 22
###begin p 23
###xml 938 940 938 940 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">36</sup>
###xml 938 940 938 940 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="bib36" ref-type="bibr"><sup>36</sup></xref>
###xml 856 859 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
In summary, 23C3 is a novel anti-osteopontin mAb with great potential for the treatment of RA. By determination of the crystal structure of 23C3 Fab in complex with its epitope peptide, we have revealed the interactions between the antibody and the peptide and identified the most important determinants for this epitope (TrpP43 and AspP47). We have also showed that FWR L2 plays an important role in the recognition and binding of the epitope by the antibody, suggesting that this region should be exploited in the development of chimeric or humanized antibodies. Besides, the detailed conformation of the epitope peptide may also be useful for the design of peptide vaccines against RA. As an example, a chemically constrained peptide mimicking the structural conformation of the epitope peptide of gp41 shows much stronger binding with the neutralizing HIV antibody 4E10 than the free peptide and therefore would be a better immunogen.36
###end p 23
###begin title 24
Protein Data Bank accession code
###end title 24
###begin p 25
The coordinates and structural factors of the 23C3 Fab fragment in complexes with its epitope peptide and the W43A mutant peptide have been deposited in the RCSB Protein Data Bank with accession codes  and , respectively.
###end p 25
###begin title 26
Supplementary data
###end title 26
###begin p 27
###xml 0 9 0 9 <title xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" textid="28">Figure S1</title>
###xml 0 9 0 9 <caption xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><title textid="28">Figure S1</title></caption>
###xml 9 9 9 9 <media xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xlink:href="mmc1.doc" mimetype="application" mime-subtype="msword"/>
###xml 0 9 0 9 <supplementary-material xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="local-data" id="N0x1d6d5d0N0x2ebf320"><caption><title textid="28">Figure S1</title></caption><media xlink:href="mmc1.doc" mimetype="application" mime-subtype="msword"/></supplementary-material>
Figure S1
###end p 27
###begin title 28
Figure S1
###end title 28
###begin title 29
Supplementary Data
###end title 29
###begin p 30
Supplementary data associated with this article can be found, in the online version, at
###end p 30
###begin title 31
Acknowledgements
###end title 31
###begin p 32
We are grateful to other members of our laboratories for technical assistance and helpful discussion. This work was supported by grants of the Ministry of Science and Technology of China (2004CB720102, 2006AA02Z112, 2006AA02A313, and 2007CB914302) and the National Natural Science Foundation of China (90713046 and 30730028).
###end p 32
###begin title 33
References
###end title 33
###begin article-title 34
Rheumatoid arthritis. Treatment of early disease
###end article-title 34
###begin article-title 35
###xml 60 64 <span type="species:ncbi:10090">mice</span>
The molecular pathogenesis of collagen-induced arthritis in mice-a model for rheumatoid arthritis
###end article-title 35
###begin article-title 36
The role of T-lymphocytes in rheumatoid arthritis
###end article-title 36
###begin article-title 37
###xml 34 42 <span type="species:ncbi:9606">patients</span>
Etanercept versus methotrexate in patients with early rheumatoid arthritis: two-year radiographic and clinical outcomes
###end article-title 37
###begin article-title 38
Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group
###end article-title 38
###begin article-title 39
###xml 51 56 <span type="species:ncbi:9606">human</span>
###xml 94 102 <span type="species:ncbi:9606">patients</span>
Dose-range and dose-frequency study of recombinant human interleukin-1 receptor antagonist in patients with rheumatoid arthritis. The IL-1Ra Arthritis Study Group
###end article-title 39
###begin article-title 40
Osteopontin as a means to cope with environmental insults: regulation of inflammation, tissue remodeling, and cell survival
###end article-title 40
###begin article-title 41
Interactions between the bone matrix proteins osteopontin and bone sialoprotein and the osteoclast integrin alphavbeta3 potentiate bone resorption
###end article-title 41
###begin article-title 42
A biochemical characterization of the binding of osteopontin to integrins alphavbeta1 and alphavbeta5
###end article-title 42
###begin article-title 43
Identification of osteopontin as a novel ligand for the integrin alpha8beta1 and potential roles for this integrin-ligand interaction in kidney morphogenesis
###end article-title 43
###begin article-title 44
The integrin a9b1 binds to a novel recognition sequence (SVVYGLR) in the thrombin-cleaved amino-terminal fragment of osteopontin
###end article-title 44
###begin article-title 45
Analysis of the alpha4beta1 integrin-osteopontin interaction
###end article-title 45
###begin article-title 46
Structural elements of the osteopontin SVVYGLR motif important for the interaction with alpha4 integrins
###end article-title 46
###begin article-title 47
CD44 variants but not CD44s cooperate with beta1-containing integrins to permit cells to bind to osteopontin independently of arginine-glycine-aspartic acid, thereby stimulating cell motility and chemotaxis
###end article-title 47
###begin article-title 48
Osteopontin: a protein with diverse functions
###end article-title 48
###begin article-title 49
Eta-1 (osteopontin): an early component of type-1 (cell-mediated) immunity
###end article-title 49
###begin article-title 50
Osteopontin has a crucial role in allergic airway disease through regulation of dendritic cell subsets
###end article-title 50
###begin article-title 51
Osteopontin as a mediator of NKT cell function in T cell-mediated liver diseases
###end article-title 51
###begin article-title 52
Osteopontin prevents monocyte recirculation and apoptosis
###end article-title 52
###begin article-title 53
Osteopontin modulates CD44-dependent chemotaxis of peritoneal macrophages through G-protein-coupled receptors: evidence of a role for an intracellular form of osteopontin
###end article-title 53
###begin article-title 54
Role of osteopontin in amplification and perpetuation of rheumatoid synovitis
###end article-title 54
###begin article-title 55
Expression of osteopontin messenger RNA and protein in rheumatoid arthritis: effects of osteopontin on the release of collagenase 1 from articular chondrocytes and synovial fibroblasts
###end article-title 55
###begin article-title 56
###xml 58 63 <span type="species:ncbi:9606">human</span>
Successful treatment of collagen-induced arthritis in non-human primates by chimeric anti-osteopontin antibody
###end article-title 56
###begin article-title 57
###xml 70 76 <span type="species:ncbi:10090">murine</span>
Essential role of the cryptic epitope SLAYGLR within osteopontin in a murine model of rheumatoid arthritis
###end article-title 57
###begin article-title 58
###xml 124 130 <span type="species:ncbi:10090">murine</span>
###xml 135 140 <span type="species:ncbi:9606">human</span>
Treatment of collagen-induced arthritis with an anti-osteopontin monoclonal antibody through promotion of apoptosis of both murine and human activated T cells
###end article-title 58
###begin article-title 59
Antibody elbow angles are influenced by their light chain class
###end article-title 59
###begin article-title 60
Standard conformations for the canonical structures of immunoglobulins
###end article-title 60
###begin article-title 61
Length distribution of CDRH3 in antibodies
###end article-title 61
###begin article-title 62
###xml 92 97 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Structure of antibody F425-B4e8 in complex with a V3 peptide reveals a new binding mode for HIV-1 neutralization
###end article-title 62
###begin article-title 63
Crystal structures of an antibody to a peptide and its complex with peptide antigen at 2.8 A
###end article-title 63
###begin article-title 64
Glycosylation of a VH residue of a monoclonal antibody against alpha (1-6) dextran increases its affinity for antigen
###end article-title 64
###begin article-title 65
Antibody-antigen interactions: new structures and new conformational changes
###end article-title 65
###begin article-title 66
Structural aspects of antibodies and antibody-antigen complexes
###end article-title 66
###begin article-title 67
Protein-peptide interactions
###end article-title 67
###begin article-title 68
Shape complementarity at protein/protein interfaces
###end article-title 68
###begin article-title 69
###xml 120 125 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Structural basis of enhanced binding of extended and helically constrained peptide epitopes of the broadly neutralizing HIV-1 antibody 4E10
###end article-title 69
###begin p 70
###xml 349 350 349 350 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">F</italic>
###xml 350 351 350 351 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">o</sub>
###xml 354 355 354 355 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">F</italic>
###xml 355 356 355 356 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">c</sub>
Overall structure of the 23C3 Fab-epitope peptide complex. (a) Stereoview of the overall structure of the 23C3 Fab-epitope peptide complex. The 23C3 Fab light chain is colored yellow, the heavy chain is cyan, and the bound peptide is purple. The sugar chain is shown with a ball-and-stick model. (b) A stereo view representation of SIGMAA-weighted 2Fo - Fc map (1sigma contour level) for the bound epitope peptide. The peptide is shown with a ball-and-stick model.
###end p 70
###begin p 71
###xml 248 253 <span type="species:ncbi:2708">lemon</span>
The interactions between the 23C3 Fab and the bound peptide. (a) An enlarged view of the interface surface. The peptide is bound at a pocket formed mainly by CDRs and interacts with CDRs L1, L3, H1, H2, and H3 and FWR L2. The Fab CDR L1 is colored lemon; L2, salmon; L3, cyan; H1, orange; H2, pink; H3, brown; FWR L2, olive; and other FWRs, silver. The peptide is colored purple. (b) A stereo view showing the hydrogen bonds between residues of the 23C3 Fab and residues of the epitope peptide. The color coding is the same as above. The residues that participate in the hydrogen-bonding interactions are shown with ball-and-stick models. (c) An electrostatic potential surface of the 23C3 Fab at the interface. The Fab accommodates the peptide with great structural and chemical complementarity. (d) The extensive hydrophobic interactions between the Fab and the key residue TrpP43 of the epitope peptide. Residues AlaL34 of CDR L1, PheL91 of CDR L3, MetH102 of CDR H3, and TyrL36, LeuL46, and TyrL49 of FWR L2 form a deep hydrophobic pocket to accommodate TrpP43 of the peptide. (e) The hydrophilic recognition of AspP47 by the Fab. AspP47 makes hydrogen-bonding interactions with SerH53, AsnH56, and ArgH52. It also forms electrostatic interactions with residues ArgH50 and ArgH52 of CDR H2. The color coding is the same as in (a).
###end p 71
###begin p 72
Summary of diffraction data and structure refinement statistics
###end p 72
###begin p 73
Numbers in parentheses refer to the highest-resolution shell.
###end p 73
###begin p 74
###xml 0 1 0 1 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">R</italic>
###xml 1 6 1 6 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">merge</sub>
###xml 27 30 10 13 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">hkl</italic>
###xml 27 30 10 13 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><italic>hkl</italic></sub>
###xml 48 49 14 15 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">i</italic>
###xml 48 49 14 15 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><italic>i</italic></sub>
###xml 50 51 16 17 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">I</italic>
###xml 51 52 17 18 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">i</italic>
###xml 51 52 17 18 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><italic>i</italic></sub>
###xml 53 56 19 22 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">hkl</italic>
###xml 57 58 23 24 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">i</italic>
###xml 57 58 23 24 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><italic>i</italic></sub>
###xml 62 63 28 29 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">I</italic>
###xml 64 67 30 33 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">hkl</italic>
###xml 89 92 38 41 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">hkl</italic>
###xml 89 92 38 41 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><italic>hkl</italic></sub>
###xml 110 111 42 43 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">i</italic>
###xml 110 111 42 43 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><italic>i</italic></sub>
###xml 111 112 43 44 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">I</italic>
###xml 112 113 44 45 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">i</italic>
###xml 112 113 44 45 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><italic>i</italic></sub>
###xml 114 117 46 49 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">hkl</italic>
Rmerge = summation operatorhklsummation operatori|Ii(hkl)i - I(hkl)|/summation operatorhklsummation operatoriIi(hkl).
###end p 74
###begin p 75
###xml 0 1 0 1 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">R</italic>
###xml 29 32 12 15 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">hkl</italic>
###xml 29 32 12 15 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><italic>hkl</italic></sub>
###xml 35 36 18 19 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">F</italic>
###xml 36 37 19 20 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">o</sub>
###xml 40 41 23 24 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">F</italic>
###xml 41 42 24 25 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">c</sub>
###xml 63 66 29 32 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">hkl</italic>
###xml 63 66 29 32 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><italic>hkl</italic></sub>
###xml 68 69 34 35 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">F</italic>
###xml 69 70 35 36 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">o</sub>
R-factor = summation operatorhkl ||Fo|-|Fc||/summation operatorhkl |Fo|.
###end p 75
###begin p 76
The hydrophilic interactions between 23C3 Fab and the peptide
###end p 76

